Waterloo Capital L.P. Trims Stake in Boston Scientific Corporation $BSX

Waterloo Capital L.P. lowered its position in Boston Scientific Corporation (NYSE:BSX) by 25.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,592 shares of the medical equipment provider’s stock after selling 886 shares during the period. Waterloo Capital L.P.’s holdings in Boston Scientific were worth $278,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Bessemer Group Inc. grew its position in Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after acquiring an additional 2,899,653 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after purchasing an additional 1,664,108 shares during the period. Swedbank AB raised its position in Boston Scientific by 114.5% during the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after purchasing an additional 1,505,019 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after buying an additional 1,383,524 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 175,782 shares of company stock worth $17,742,314. Insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. BTIG Research restated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a report on Friday, November 21st. Needham & Company LLC restated a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a report on Friday, October 17th. Morgan Stanley increased their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a report on Monday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Trading Up 3.4%

Shares of NYSE:BSX opened at $101.37 on Wednesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm has a market capitalization of $150.27 billion, a P/E ratio of 54.21, a P/E/G ratio of 2.02 and a beta of 0.58. The business’s 50-day moving average is $98.98 and its 200 day moving average is $102.30. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.